According to Zhitong Finance App, Tongyuankang Pharmaceutical-B (02410.HK) announced that the company's chairman, executive director and president, Dr. Wu Yusheng, informed the company that from September 8, 2026 to September 10, 2026, it purchased 635,000 H shares of the company on the open market (accounting for about 0.17% of the company's total issued share capital), at a total cost of about HK$2.09 million. Dr. Wu Yusheng has informed the company that it may continue to buy shares in the company in the future according to market conditions. It is currently anticipated that the total amount of further shares purchased on this basis will not exceed HK$3 million. Dr. Wu Yusheng said that the capital for the acquisition of these shares came from his own funds. This further increase in shareholding shows its firm belief and full confidence in the Group's future development prospects.

According to Zhitong Finance App, Tongyuankang Pharmaceutical-B (02410.HK) announced that the company's chairman, executive director and president, Dr. Wu Yusheng, informed the company that from September 8, 2026 to September 10, 2026, it purchased 635,000 H shares of the company on the open market (accounting for about 0.17% of the company's total issued share capital), at a total cost of about HK$2.09 million. Dr. Wu Yusheng has informed the company that it may continue to buy shares in the company in the future according to market conditions. It is currently anticipated that the total amount of further shares purchased on this basis will not exceed HK$3 million. Dr. Wu Yusheng said that the capital for the acquisition of these shares came from his own funds. This further increase in shareholding shows its firm belief and full confidence in the Group's future development prospects.